Evaluation of recurrent or metastatic solid tumor patients on Kanitinib single dose and continuous multiple dose safety and tolerability, and to determine the maximum tolerated Connie imatinib dose (MTD) or the phase II trial recommended dosage.
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.